Abstract:Successful development of treatments for non-alcoholic fatty liver disease and its progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because NASH and fibrosis lead to progression towards cirrhosis and clinical outcomes, approaches have either sought to attenuate metabolic dysregulation and cell injury, or directly target the inflammation and fibrosis that ensue. Targets for reducing the activation of inflammatory cascades include nuclear receptor agonists (e.g. resmetirom, lanifibranor, obeticholic acid), modulators of lipotoxicity (e.g. aramchol, acetyl-CoA carboxylase inhibitors) or modification of genetic variants (e.g. PNPLA3 gene silencing). Extrahepatic inflammatory signals from the circulation, adipose tissue or gut are targets of hormonal agonists (semaglutide, tirzepatide, FGF19/FGF21 analogues), microbiota or lifestyle interventions. Stress signals and hepatocyte death activate immune responses, engaging innate (macrophages, innate lymphocyte populations) and adaptive (auto-aggressive T cells) mechanisms. Therapies have also been developed to blunt immune cell activation, recruitment (chemokine receptor inhibitors), and responses (e.g. galectin-3 inhibitors, anti-platelet drugs). The disease-driving pathways of NASH converge to elicit fibrosis, which is reversible. The activation of hepatic stellate cells into matrix-producing myofibroblasts can be inhibited by antagonising soluble factors (e.g. integrins, cytokines), cellular crosstalk (e.g. with macrophages), and agonising nuclear receptor signalling. In advanced fibrosis, cell therapy with restorative macrophages or reprogrammed (CAR) T cells may accelerate repair through hepatic stellate cell deactivation or killing, or by enhancing matrix degradation. Heterogeneity of disease - either due to genetics or divergent disease drivers - is an obstacle to defining effective drugs for all patients with NASH that will be overcome incrementally.

Current Evaluation of the Safety and Efficacy of Aneurysm Treatment with the WEB Device

Parallel Text Document Clustering Based on Genetic Algorithm

Current and new pharmacotherapy options for non-alcoholic steatohepatitis

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

Patency of heparinized SBS shunts at high shear rates.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis

[Pharmacological properties of a specific Gq/11 inhibitor, YM-254890].

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Effect of auditory deafferentation on the synaptic connectivity of a pair of identified interneurons in adult field crickets.

Dcp1 links coactivators of mRNA decapping to Dcp2 by proline recognition.

Efficacy and safety of drugs for nonalcoholic steatohepatitis

Adding Multilingual Information Access to the European Library

Advancements in Non-Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Treatment: From Lifestyle Interventions to Novel Therapies